Cargando…
Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
BACKGROUND: Ceftolozane-tazobactam (TOL-TAZ) is a novel cephalosporin/β-lactamase inhibitor combination with potent activity against Pseudomonas aeruginosa, including MDRPA. TOL-TAZ use for MDRPA infections has not been well-studied. METHODS: We conducted a retrospective study to describe outcomes o...
Autores principales: | Molnar, Esther, Heil, Emily, Claeys, Kimberly, Hiles, Jon, Gallagher, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632154/ http://dx.doi.org/10.1093/ofid/ofx163.643 |
Ejemplares similares
-
2382. Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients: A Multi-Center Study
por: Elabor, Abdulrahman, et al.
Publicado: (2018) -
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
por: Gallagher, Jason C, et al.
Publicado: (2018) -
2435. Clinical Outcomes With Ceftolozane–Tazobactam in Patients With Multidrug-Resistant (MDR) Pseudomonas aeruginosa Bloodstream Infections: A Multi-Center Study
por: King, Madeline, et al.
Publicado: (2018) -
292. Ceftolozane/Tazobactam for Treatment of Osteomyelitis due to Multi-Drug-Resistant Pseudomonas aeruginosa
por: Gerlach, Anthony, et al.
Publicado: (2018) -
2286. Evaluating the Impact of Ceftolozane/Tazobactam on Clinical Outcomes in Patients with Multi-Drug-resistant Pseudomonas aeruginosa Pneumonia
por: Mills, Matthew, et al.
Publicado: (2019)